{{Drugbox
| Watchedfields = changed
| verifiedrevid = 458783301
| image = Azacitidine.svg
| width =
| alt =
| tradename = Vidaza, Azadine, Onureg
| Drugs.com = {{drugs.com|monograph|azacitidine}}
| MedlinePlus = a607068
| licence_EU = yes
| DailyMedID = Azacitidine
| pregnancy_AU      = X
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Azacitidine (Vidaza) Use During Pregnancy | website=Drugs.com | date=2020-05-05 | url=https://www.drugs.com/pregnancy/azacitidine.html | access-date=2020-08-12 | archive-date=2020-12-05 | archive-url=https://web.archive.org/web/20201205061121/https://www.drugs.com/pregnancy/azacitidine.html | dead-url=no }}</ref>
| pregnancy_US      = N
| pregnancy_US_comment = <ref name="Drugs.com pregnancy" />
| pregnancy_category =
| routes_of_administration = [[皮下注射|皮下注射]]、[[静脉注射|静脉注射]]、[[口服|口服]]
| ATC_prefix = L01
| ATC_suffix = BC07

| legal_AU = S4
| legal_US = Rx-only
| legal_US_comment = <ref name="Vidaza FDA label">{{cite web | title=Vidaza- azacitidine injection, powder, lyophilized, for solution | website=DailyMed | date=2020-03-02 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3495a71a-cc04-4776-851f-f185956f32af | access-date=2020-09-27 | archive-date=2021-11-05 | archive-url=https://web.archive.org/web/20211105012720/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3495a71a-cc04-4776-851f-f185956f32af | dead-url=no }}</ref>
| legal_EU = Rx-only
| legal_status =  
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism = 主要经肾排出，部分可能经肝代谢
| elimination_half-life = 4小时<ref>{{cite book | first1 = April Hazard | last1 = Vallerand | first2 = Judith Hopfer | last2 = Deglin | date = 2009 | title = Davis's drug guide for nurses. | url = https://archive.org/details/davissdrugguidef00degl_470 | location = Philadelphia | publisher = F.A. Davis Company | pages = [https://archive.org/details/davissdrugguidef00degl_470/page/n232 204]–206 | isbn = 978-0-8036-1912-8 }}</ref>
<!--Identifiers-->
| IUPHAR_ligand = 6796
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 320-67-2
| PubChem = 9444
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00928
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9072
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = M801H13NRU
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03021
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2038
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1489
| synonyms = 5-Azacytidine (5-AZA), Azacytidine, Ladakamycin, 4-Amino-1-β-D-ribofuranosyl-s-triazin-2(1''H'')-one, U-18496, CC-486
| IUPAC_name = 4-Amino-1-β-<small>D</small>-ribofuranosyl-1,3,5-triazin-2(1''H'')-one
| C=8 | H=12 | N=4 | O=5 
| smiles = O=C1/N=C(\N=C/N1[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NMUSYJAQQFHJEW-KVTDHHQDSA-N
}}
'''阿扎胞苷'''（[[国际非专利药品名称|INN]]：Azacitidine），有时也称为'''5-阿扎胞苷'''（5-Azacitidine），商品名维达莎或委丹扎（Vidaza），是一种[[胞苷|胞苷]]（组成[[DNA|DNA]]与[[RNA|RNA]]的[[核苷|核苷]]之一）[[结构类似物|类似物]]，由[[捷克斯洛伐克|捷克斯洛伐克]]学者{{link-en|弗朗蒂斯克·索姆|František Šorm}}（{{lang|cs|František Šorm}}）于20世纪60年代首先合成用于[[肿瘤|肿瘤]][[化疗|化疗]]<ref name="KhanPathe2012">{{cite journal|last1=Khan|first1=Cyrus|last2=Pathe|first2=Neeta|last3=Fazal|first3=Salman|last4=Lister|first4=John|last5=Rossetti|first5=James M.|title=Azacitidine in the management of patients with myelodysplastic syndromes|journal=Therapeutic Advances in Hematology|volume=3|issue=6|year=2012|pages=355–373|issn=2040-6207|doi=10.1177/2040620712464882}}</ref>，目前主要用于治疗[[骨髓增生异常综合征|骨髓增生异常综合征]]<ref name="BucksteinYee2011">{{cite journal|last1=Buckstein|first1=Rena|last2=Yee|first2=Karen|last3=Wells|first3=Richard A.|title=5-Azacytidine in myelodysplastic syndromes: A clinical practice guideline|journal=Cancer Treatment Reviews|volume=37|issue=2|year=2011|pages=160–167|issn=03057372|doi=10.1016/j.ctrv.2010.05.006}}</ref>。阿扎胞苷目前也是一种在生物医学研究中常用的[[DNA甲基化|DNA甲基化]]抑制剂<ref>{{cite journal |author1=Christina M. Bender |coauthors=etal |title=Inhibition of DNA Methylation by 5-Aza-2′-deoxycytidine Suppresses the Growth of Human Tumor Cell Lines |journal=Cancer Research |date=1998 |volume=58 |issue=1 |pmid=9426064 |url=https://cancerres.aacrjournals.org/content/58/1/95.short |accessdate=2021-03-28}}</ref><ref name="JonesTaylor1983">{{cite journal|last1=Jones|first1=P. A.|last2=Taylor|first2=S. M.|last3=Wilson|first3=V. L.|title=Inhibition of DNA Methylation by 5-Azacytidine|year=1983|pages=202–211|doi=10.1007/978-3-642-81947-6_15}}</ref>。

阿扎胞苷有一种脱氧衍生物[[地西他滨|地西他滨]]<ref name="DerissenBeijnen2013">{{cite journal|last1=Derissen|first1=Ellen J.B.|last2=Beijnen|first2=Jos H.|last3=Schellens|first3=Jan H.M.|title=Concise Drug Review: Azacitidine and Decitabine|journal=The Oncologist|volume=18|issue=5|year=2013|pages=619–624|issn=1083-7159|doi=10.1634/theoncologist.2012-0465}}</ref>。

==作用机理==
阿扎胞苷是一种[[胞苷|胞苷]][[结构类似物|类似物]]。在低剂量时，阿扎胞苷能够通过与DNA甲基化酶{{link-en|DNA甲基转移酶|DNA methyltransferase|DNMT蛋白家族}}形成共价键抑制其酶活性，使细胞的[[DNA甲基化|DNA甲基化]]水平降低<ref name="SprangersCosmai2020">{{cite journal|last1=Sprangers|first1=Ben|last2=Cosmai|first2=Laura|last3=Porta|first3=Camillo|title=Conventional chemotherapy|year=2020|pages=127–153.e11|doi=10.1016/B978-0-323-54945-5.00025-4}}</ref><ref name="RajMufti2006"/>。因为阿扎胞苷的这一性质，在生物医学研究中，研究者常常将阿扎胞苷用作DNA甲基化抑制剂<ref name="JonesTaylor1983"/>。而在高剂量时，阿扎胞苷能直接插入细胞的DNA与RNA中，分別干扰DNA代谢和阻断RNA[[轉譯|翻译]]的過程，從而抑制蛋白質的合成，由此产生细胞毒性，令细胞死亡<ref name="ZhuQian2015">{{cite journal|last1=Zhu|first1=Wei|last2=Qian|first2=Jiaqi|title=Clinical Trials|year=2015|pages=525–568|doi=10.1016/B978-0-12-800206-3.00023-9}}</ref><ref name="GersonCaimi2018">{{cite journal|last1=Gerson|first1=Stanton L.|last2=Caimi|first2=Paolo F.|last3=William|first3=Basem M.|last4=Creger|first4=Richard J.|title=Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies|year=2018|pages=849–912|doi=10.1016/B978-0-323-35762-3.00057-3}}</ref>。

==药代动力学==
经[[皮下注射|皮下注射]]后，阿扎胞苷能快速被吸收，生物利用度可达89%。在人体内阿扎胞苷的半衰期约为4小时。代谢方面，主要经[[肾脏|肾脏]]排出<ref name=Drugbank-5Aza>{{cite web|url=https://go.drugbank.com/drugs/DB00928|title=Azacitidine|website=Drugbank|access-date=2021-03-28|archive-date=2021-05-17|archive-url=https://web.archive.org/web/20210517065753/https://go.drugbank.com/drugs/DB00928|dead-url=no}}</ref>。

==毒性==
阿扎胞苷可能造成[[贫血|贫血]]、[[嗜中性白血球低下|嗜中性白血球低下]]，以及{{le|血小板减少症|Thrombocytopenia}}等[[药物不良反应|药物不良反应]]<ref name="Vidaza FDA label">{{cite web | title=Vidaza- azacitidine injection, powder, lyophilized, for solution | website=DailyMed | date=2020-03-02 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3495a71a-cc04-4776-851f-f185956f32af | access-date=2020-09-27}}</ref>。此外，在存在严重[[肝|肝]]功能障碍的病人中，阿扎胞苷可能产生肝毒性。与其他化疗药物同时使用时，可能造成程度不一的肾毒性<ref name="Vidaza FDA label"/>。此外，也有过量给予阿扎胞苷造成患者腹泻、恶心和呕吐的报告<ref name=Drugbank-5Aza/>。

==临床应用==
目前阿扎胞苷主要用于治疗[[骨髓增生异常综合征|骨髓增生异常综合征]]。2004年，[[美国食品药品监督管理局|美国食品药品监督管理局]]（FDA）批准将阿扎胞苷用于骨髓增生异常综合征治疗中<ref name="RajMufti2006">{{cite journal|last1=Raj|first1=Kavita|last2=Mufti|first2=Ghulam J|title=Azacytidine (Vidaza) in the treatment of myelodysplastic syndromes|journal=Therapeutics and Clinical Risk Management|volume=2|issue=4|year=2006|pages=377–388|issn=1176-6336|doi=10.2147/tcrm.2006.2.4.377}}</ref>。除此之外，阿扎胞苷偶尔也被用于[[急性骨髓性白血病|急性骨髓性白血病]]的[[化学治疗|化学治疗]]中<ref name=Estey2013>{{cite journal | vauthors = Estey EH | title = Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia | journal = Leukemia | volume = 27 | issue = 9 | pages = 1803–12 | date = September 2013 | pmid = 23757301 | doi = 10.1038/leu.2013.173}}</ref>。

此外，一些[[动物实验|动物实验]]结果表明阿扎胞苷有抗病毒作用，但目前为止阿扎胞苷尚未被批准用于抗病毒治疗中<ref>{{cite journal | vauthors = Wang X, Zou P, Wu F, Lu L, Jiang S | title = Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses | journal = Frontiers of Medicine | volume = 11 | issue = 4 | pages = 449–461 | date = December 2017 | pmid = 29170916 | doi = 10.1007/s11684-017-0589-5 | pmc = 7089273 }}</ref><ref>{{cite journal | vauthors = Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Bjørås M, Nordbø SA, Dumpis U, Vitkauskiene A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, Kainov D | display-authors = 6 | title = Novel activities of safe-in-human broad-spectrum antiviral agents | journal = Antiviral Research | volume = 154 | pages = 174–182 | date = June 2018 | pmid = 29698664 | doi = 10.1016/j.antiviral.2018.04.016 | pmc = 7113852 | hdl = 10138/301108}}</ref>。

==参见==
*[[DNA甲基化|DNA甲基化]]

==参考文献==
{{reflist|2}}

{{化疗药物}}

[[Category:抗肿瘤药|Category:抗肿瘤药]]
[[Category:IARC第2A类致癌物质|Category:IARC第2A类致癌物质]]
[[Category:核苷|Category:核苷]]
[[Category:三嗪|Category:三嗪]]
[[Category:内酰胺|Category:内酰胺]]